Skip to main content
. 2018 Jan 16;2018(1):CD006847. doi: 10.1002/14651858.CD006847.pub2

Comparison 7. Gefitinib 250 mg versus gefitinib 500 mg.

Outcome or subgroup title No. of studies No. of participants Statistical method Effect size
1 1‐year survival rate 2 424 Risk Ratio (M‐H, Fixed, 95% CI) 0.83 [0.61, 1.11]
1.1 2nd line 2 424 Risk Ratio (M‐H, Fixed, 95% CI) 0.83 [0.61, 1.11]
2 Skin rash 2 290 Risk Ratio (M‐H, Fixed, 95% CI) 8.13 [1.51, 43.72]
2.1 2nd line 1 209 Risk Ratio (M‐H, Fixed, 95% CI) 6.80 [0.85, 54.32]
2.2 Maintenance 1 81 Risk Ratio (M‐H, Fixed, 95% CI) 10.41 [0.61, 176.21]
3 Acne 1 209 Risk Ratio (M‐H, Fixed, 95% CI) 4.86 [0.24, 100.02]
3.1 2nd line 1 209 Risk Ratio (M‐H, Fixed, 95% CI) 4.86 [0.24, 100.02]
4 Pruritus 1 209 Risk Ratio (M‐H, Fixed, 95% CI) 2.92 [0.12, 70.77]
4.1 2nd line 1 209 Risk Ratio (M‐H, Fixed, 95% CI) 2.92 [0.12, 70.77]
5 Diarrhoea 3 521 Risk Ratio (M‐H, Fixed, 95% CI) 8.36 [1.58, 44.34]
5.1 2nd line 3 521 Risk Ratio (M‐H, Fixed, 95% CI) 8.36 [1.58, 44.34]
6 Nausea 1 209 Risk Ratio (M‐H, Fixed, 95% CI) 0.97 [0.06, 15.33]
6.1 2nd line 1 209 Risk Ratio (M‐H, Fixed, 95% CI) 0.97 [0.06, 15.33]
7 Vomiting 1 209 Risk Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.1 2nd line 1 209 Risk Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8 Anorexia 1 209 Risk Ratio (M‐H, Fixed, 95% CI) 2.92 [0.12, 70.77]
8.1 2nd line 1 209 Risk Ratio (M‐H, Fixed, 95% CI) 2.92 [0.12, 70.77]
9 Asthenia 1 209 Risk Ratio (M‐H, Fixed, 95% CI) 2.92 [0.12, 70.77]
9.1 2nd line 1 209 Risk Ratio (M‐H, Fixed, 95% CI) 2.92 [0.12, 70.77]
10 Overall response rate 3   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
10.1 2nd line 2 424 Risk Ratio (M‐H, Fixed, 95% CI) 0.92 [0.58, 1.46]
10.2 Maintenance 1 96 Risk Ratio (M‐H, Fixed, 95% CI) 1.0 [0.35, 2.88]
11 Partial response 1 216 Risk Ratio (M‐H, Fixed, 95% CI) 0.75 [0.34, 1.65]
11.1 2nd line 1 216 Risk Ratio (M‐H, Fixed, 95% CI) 0.75 [0.34, 1.65]
12 FACT‐L Symptom improvement rate 2 356 Mean Difference (IV, Fixed, 95% CI) 3.70 [‐7.28, 14.69]
12.1 2nd line 2 356 Mean Difference (IV, Fixed, 95% CI) 3.70 [‐7.28, 14.69]
13 TOI QOL improvement rate 2 424 Mean Difference (IV, Fixed, 95% CI) 7.38 [‐2.30, 17.05]
13.1 2nd line 2 424 Mean Difference (IV, Fixed, 95% CI) 7.38 [‐2.30, 17.05]